Regeneron supplies gene technology to Sanofi-Aventis
This article was originally published in Scrip
Executive Summary
Regeneron Pharmaceuticals is to receive a minimum annual payment of $4.3 million from Sanofi-Aventis for the use of its gene technology platform, Velocigene. The payment, to be made over five years, will be for knock-out and transgenic models of gene function for target genes that Sanofi-Aventis identifies. Sanofi-Aventis will use these models for its internal research programmes outside the antibody collaboration that the two companies started in November 2007 for the development of human therapeutic antibodies (Scrip No 3317, p7).